{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:42:18Z","timestamp":1792698138566,"version":"4.5.0"},"reference-count":236,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-11156-1","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:22:26Z","timestamp":1792650146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging links between gut dysbiosis, aryl hydrocarbon receptor activation, and Parkinson\u2019s disease"],"prefix":"10.1038","volume":"9","author":[{"given":"Nastaran Farshchi","family":"Aziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3532-8669","authenticated-orcid":false,"given":"Sandhya","family":"Kortagere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"11156_CR1","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1460-9568.2009.06873.x","volume":"30","author":"T Lebouvier","year":"2009","unstructured":"Lebouvier, T. et al. The second brain and Parkinson\u2019s disease. Eur. J. Neurosci. 30, 735\u2013741 (2009).","journal-title":"Eur. J. Neurosci."},{"key":"11156_CR2","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.parkreldis.2007.06.003","volume":"13","author":"LJ Findley","year":"2007","unstructured":"Findley, L. J. The economic impact of Parkinson\u2019s disease. Parkinsonism Relat. Disord. 13, S8\u2013S12 (2007).","journal-title":"Parkinsonism Relat. Disord."},{"key":"11156_CR3","doi-asserted-by":"crossref","unstructured":"Luo, Y., et al., Global, regional, national epidemiology and trends of Parkinson\u2019s disease from 1990 to 2021: Findings from the Global Burden of Disease Study 2021. Front. Aging Neurosci. 2025. Volume 16 - 2024.","DOI":"10.3389\/fnagi.2024.1498756"},{"key":"11156_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.neubiorev.2016.07.010","volume":"68","author":"AA Moustafa","year":"2016","unstructured":"Moustafa, A. A. et al. Motor symptoms in Parkinson\u2019s disease: A unified framework. Neurosci. Biobehav. Rev. 68, 727\u2013740 (2016).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"11156_CR5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1468-1331.2008.02056.x","volume":"15","author":"W Poewe","year":"2008","unstructured":"Poewe, W. Non-motor symptoms in Parkinson\u2019s disease. Eur. J. Neurol. 15, 14\u201320 (2008).","journal-title":"Eur. J. Neurol."},{"key":"11156_CR6","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/mds.26307","volume":"30","author":"A Keshavarzian","year":"2015","unstructured":"Keshavarzian, A. et al. Colonic bacterial composition in Parkinson\u2019s disease. Mov. Disord. 30, 1351\u20131360 (2015).","journal-title":"Mov. Disord."},{"key":"11156_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16790-8","volume":"8","author":"Q-J Yu","year":"2018","unstructured":"Yu, Q.-J. et al. Parkinson disease with constipation: clinical features and relevant factors. Sci. Rep. 8, 567 (2018).","journal-title":"Sci. Rep."},{"key":"11156_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41392-024-01743-1","volume":"9","author":"JS Loh","year":"2024","unstructured":"Loh, J. S. et al. Microbiota\u2013gut\u2013brain axis and its therapeutic applications in neurodegenerative diseases. Signal Transduct. Target. Ther. 9, 37 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"11156_CR9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00401-014-1343-6","volume":"128","author":"S Holmqvist","year":"2014","unstructured":"Holmqvist, S. et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 128, 805\u2013820 (2014).","journal-title":"Acta Neuropathol."},{"key":"11156_CR10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1002\/ana.24448","volume":"78","author":"E Svensson","year":"2015","unstructured":"Svensson, E. et al. Vagotomy and subsequent risk of P arkinson\u2019s disease. Ann. Neurol. 78, 522\u2013529 (2015).","journal-title":"Ann. Neurol."},{"key":"11156_CR11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","volume":"103","author":"S Kim","year":"2019","unstructured":"Kim, S. et al. Transneuronal propagation of pathologic \u03b1-synuclein from the gut to the brain models Parkinson\u2019s disease. Neuron 103, 627\u2013641. e7 (2019).","journal-title":"Neuron"},{"key":"11156_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/1735-1995.181989","volume":"21","author":"FN Emamzadeh","year":"2016","unstructured":"Emamzadeh, F. N. Alpha-synuclein structure, functions, and interactions. J. Res. Med. Sci. 21, 29 (2016).","journal-title":"J. Res. Med. Sci."},{"key":"11156_CR13","doi-asserted-by":"publisher","first-page":"a024091","DOI":"10.1101\/cshperspect.a024091","volume":"8","author":"J Burr\u00e9","year":"2018","unstructured":"Burr\u00e9, J., Sharma, M. & S\u00fcdhof, T. C. Cell biology and pathophysiology of \u03b1-synuclein. Cold Spring Harb. Perspect. Med. 8, a024091 (2018).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"11156_CR14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/35081564","volume":"2","author":"M Goedert","year":"2001","unstructured":"Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492\u2013501 (2001).","journal-title":"Nat. Rev. Neurosci."},{"key":"11156_CR15","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/brain\/awt037","volume":"136","author":"M Masuda-Suzukake","year":"2013","unstructured":"Masuda-Suzukake, M. et al. Prion-like spreading of pathological \u03b1-synuclein in brain. Brain 136, 1128\u20131138 (2013).","journal-title":"Brain"},{"key":"11156_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neulet.2005.11.012","volume":"396","author":"H Braak","year":"2006","unstructured":"Braak, H. et al. Gastric alpha-synuclein immunoreactive inclusions in Meissner\u2019s and Auerbach\u2019s plexuses in cases staged for Parkinson\u2019s disease-related brain pathology. Neurosci. Lett. 396, 67\u201372 (2006).","journal-title":"Neurosci. Lett."},{"key":"11156_CR17","doi-asserted-by":"crossref","unstructured":"Roth, W. et al. Tryptophan metabolism and gut-brain homeostasis. Int. J. Mol. Sci. 22, 2973 (2021).","DOI":"10.3390\/ijms22062973"},{"key":"11156_CR18","doi-asserted-by":"publisher","first-page":"S2097","DOI":"10.4137\/IJTR.S2097","volume":"2","author":"Y Chen","year":"2009","unstructured":"Chen, Y. & Guillemin, G. J. Kynurenine pathway metabolites in humans: disease and healthy states. Int. J. Tryptophan Res. 2, S2097 (2009). IJTR.","journal-title":"Int. J. Tryptophan Res."},{"key":"11156_CR19","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/08982104.2024.2346986","volume":"34","author":"C-M Chen","year":"2024","unstructured":"Chen, C.-M. et al. Neuroprotection effects of kynurenic acid-loaded micelles for the Parkinson\u2019s disease models. J. Liposome Res. 34, 593\u2013604 (2024).","journal-title":"J. Liposome Res."},{"key":"11156_CR20","doi-asserted-by":"publisher","first-page":"903526","DOI":"10.3389\/fimmu.2022.903526","volume":"13","author":"X Ye","year":"2022","unstructured":"Ye, X. et al. Dual role of indoles derived from intestinal microbiota on human health. Front Immunol. 13, 903526 (2022).","journal-title":"Front Immunol."},{"key":"11156_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.bbr.2014.07.037","volume":"277","author":"M Politis","year":"2015","unstructured":"Politis, M. & Niccolini, F. Serotonin in Parkinson\u2019s disease. Behav. Brain Res 277, 136\u2013145 (2015).","journal-title":"Behav. Brain Res"},{"key":"11156_CR22","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/02698811221144636","volume":"37","author":"L Nobis","year":"2023","unstructured":"Nobis, L. et al. Role of serotonin in modulation of decision-making in Parkinson\u2019s disease. J. Psychopharmacol. 37, 420\u2013431 (2023).","journal-title":"J. Psychopharmacol."},{"key":"11156_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.neuropharm.2011.01.006","volume":"61","author":"SK Tan","year":"2011","unstructured":"Tan, S. K. et al. Serotonin-dependent depression in Parkinson\u2019s disease: a role for the subthalamic nucleus? Neuropharmacology 61, 387\u2013399 (2011).","journal-title":"Neuropharmacology"},{"key":"11156_CR24","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"11156_CR25","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1093\/brain\/awp150","volume":"132","author":"Y Temel","year":"2009","unstructured":"Temel, Y. et al. Parkinson\u2019s disease, DBS and suicide: a role for serotonin? Brain 132, e126 (2009). author reply e127.","journal-title":"Brain"},{"key":"11156_CR26","doi-asserted-by":"publisher","first-page":"S174","DOI":"10.1002\/mds.22792","volume":"25","author":"M Carta","year":"2010","unstructured":"Carta, M. et al. Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson\u2019s disease. Mov. Disord. 25, S174\u2013S179 (2010).","journal-title":"Mov. Disord."},{"key":"11156_CR27","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s00702-010-0571-8","volume":"118","author":"M Gerlach","year":"2011","unstructured":"Gerlach, M. et al. Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson\u2019s disease. J. Neural Transm. (Vienna) 118, 1733\u20131742 (2011).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"11156_CR28","first-page":"370190","volume":"2012","author":"E Shin","year":"2012","unstructured":"Shin, E., Tronci, E. & Carta, M. Role of serotonin neurons in L-DOPA- and graft-induced dyskinesia in a Rat model of Parkinson\u2019s disease. Parkinsons Dis. 2012, 370190 (2012).","journal-title":"Parkinsons Dis."},{"key":"11156_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00213-007-1030-6","volume":"197","author":"WL Kuan","year":"2008","unstructured":"Kuan, W. L., Zhao, J. W. & Barker, R. A. The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson\u2019s disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Psychopharmacol. (Berl.) 197, 279\u2013293 (2008).","journal-title":"Psychopharmacol. (Berl.)"},{"key":"11156_CR30","doi-asserted-by":"publisher","first-page":"1750596","DOI":"10.3389\/fpsyt.2026.1750596","volume":"17","author":"DY Liu","year":"2026","unstructured":"Liu, D. Y. et al. Case Report: Pharmacogenetically-triggered fatal serotonin syndrome following sequential serotonergic therapy in Parkinson\u2019s disease: A case highlighting the role of CYP2D6*10\/*10 genotype and multifactorial drug interactions. Front Psychiatry 17, 1750596 (2026).","journal-title":"Front Psychiatry"},{"key":"11156_CR31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.sjpmh.2024.07.002","volume":"18","author":"M Sancho-Alonso","year":"2025","unstructured":"Sancho-Alonso, M. et al. New insights into the effects of serotonin on Parkinson\u2019s disease and depression through its role in the gastrointestinal tract. Span. J. Psychiatry Ment. Health 18, 216\u2013227 (2025).","journal-title":"Span. J. Psychiatry Ment. Health"},{"key":"11156_CR32","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1080\/19490976.2020.1758008","volume":"11","author":"N Ma","year":"2020","unstructured":"Ma, N. et al. Host\u2013microbiome interactions: the aryl hydrocarbon receptor as a critical node in tryptophan metabolites to brain signaling. Gut microbes 11, 1203\u20131219 (2020).","journal-title":"Gut microbes"},{"key":"11156_CR33","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/nmo.12617","volume":"27","author":"DM Kendig","year":"2015","unstructured":"Kendig, D. M. & Grider, J. R. Serotonin and colonic motility. Neurogastroenterol. Motil. 27, 899\u2013905 (2015).","journal-title":"Neurogastroenterol. Motil."},{"key":"11156_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24213-5","volume":"8","author":"C Manzella","year":"2018","unstructured":"Manzella, C. et al. Serotonin is an endogenous regulator of intestinal CYP1A1 via AhR. Sci. Rep. 8, 6103 (2018).","journal-title":"Sci. Rep."},{"key":"11156_CR35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fcell.2016.00045","volume":"4","author":"S Mulero-Navarro","year":"2016","unstructured":"Mulero-Navarro, S. & Fernandez-Salguero, P. M. New trends in aryl hydrocarbon receptor biology. Front. Cell Dev. Biol. 4, 45 (2016).","journal-title":"Front. Cell Dev. Biol."},{"key":"11156_CR36","first-page":"126","volume":"54","author":"CR Manzella","year":"2020","unstructured":"Manzella, C. R. et al. Serotonin modulates AhR activation by interfering with CYP1A1-mediated clearance of AhR ligands. Cell Physiol. Biochem 54, 126\u2013141 (2020).","journal-title":"Cell Physiol. Biochem"},{"key":"11156_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33858-w","volume":"13","author":"S Dai","year":"2022","unstructured":"Dai, S. et al. Structural insight into the ligand binding mechanism of aryl hydrocarbon receptor. Nat. Commun. 13, 6234 (2022).","journal-title":"Nat. Commun."},{"key":"11156_CR38","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.str.2017.05.008","volume":"25","author":"KW Schulte","year":"2017","unstructured":"Schulte, K. W. et al. Structural basis for aryl hydrocarbon receptor-mediated gene activation. Structure 25, 1025\u20131033.e3 (2017).","journal-title":"Structure"},{"key":"11156_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0009-2797(02)00064-9","volume":"141","author":"JR Petrulis","year":"2002","unstructured":"Petrulis, J. R. & Perdew, G. H. The role of chaperone proteins in the aryl hydrocarbon receptor core complex. Chem. -Biol. Interact. 141, 25\u201340 (2002).","journal-title":"Chem. -Biol. Interact."},{"key":"11156_CR40","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1021\/acs.chemrestox.9b00476","volume":"33","author":"MN Avilla","year":"2020","unstructured":"Avilla, M. N. et al. The Ah receptor: Adaptive metabolism, ligand diversity, and the xenokine model. Chem. Res. Toxicol. 33, 860\u2013879 (2020).","journal-title":"Chem. Res. Toxicol."},{"key":"11156_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/toxsci\/kfr218","volume":"124","author":"MS Denison","year":"2011","unstructured":"Denison, M. S. et al. Exactly the same but different: Promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (Dioxin) receptor. Toxicol. Sci. 124, 1\u201322 (2011).","journal-title":"Toxicol. Sci."},{"key":"11156_CR42","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/aje\/kwm371","volume":"167","author":"D Consonni","year":"2008","unstructured":"Consonni, D. et al. Mortality in a population exposed to dioxin after the Seveso, Italy, Accident in 1976: 25 years of follow-up. Am. J. Epidemiol. 167, 847\u2013858 (2008).","journal-title":"Am. J. Epidemiol."},{"key":"11156_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20572-2","volume":"12","author":"JC Granados","year":"2022","unstructured":"Granados, J. C. et al. AHR is a master regulator of diverse pathways in endogenous metabolism. Sci. Rep. 12, 16625 (2022).","journal-title":"Sci. Rep."},{"key":"11156_CR44","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1124\/mol.118.112151","volume":"93","author":"M Stepankova","year":"2018","unstructured":"Stepankova, M. et al. Methylindoles and methoxyindoles are agonists and antagonists of human aryl hydrocarbon receptor. Mol. Pharm. 93, 631\u2013644 (2018).","journal-title":"Mol. Pharm."},{"key":"11156_CR45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cotox.2017.01.001","volume":"2","author":"EJ Wright","year":"2017","unstructured":"Wright, E. J. et al. Canonical and non-canonical aryl hydrocarbon receptor signaling pathways. Curr. Opin. Toxicol. 2, 87\u201392 (2017).","journal-title":"Curr. Opin. Toxicol."},{"key":"11156_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41392-025-02500-8","volume":"11","author":"X Coumoul","year":"2026","unstructured":"Coumoul, X. et al. The aryl hydrocarbon receptor: structure, signaling, physiology and pathology. Signal Transduct. Target. Ther. 11, 20 (2026).","journal-title":"Signal Transduct. Target. Ther."},{"key":"11156_CR47","doi-asserted-by":"publisher","first-page":"26261","DOI":"10.1074\/jbc.271.42.26261","volume":"271","author":"Y-H Chen","year":"1996","unstructured":"Chen, Y.-H. & Tukey, R. H. Protein kinase C modulates regulation of the <em>CYP1A1<\/em> gene by the aryl hydrocarbon receptor *. J. Biol. Chem. 271, 26261\u201326266 (1996).","journal-title":"J. Biol. Chem."},{"key":"11156_CR48","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0006-2952(98)00208-1","volume":"56","author":"W Li","year":"1998","unstructured":"Li, W. et al. Regulation of cytochrome P450 enzymes by aryl hydrocarbon receptor in human cells: CYP1A2 expression in the LS180 colon carcinoma cell line after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or 3-methylcholanthrene. Biochem. Pharmacol. 56, 599\u2013612 (1998).","journal-title":"Biochem. Pharmacol."},{"key":"11156_CR49","doi-asserted-by":"publisher","first-page":"21050","DOI":"10.1039\/C9RA03674A","volume":"9","author":"BR Shah","year":"2019","unstructured":"Shah, B. R., Xu, W. & Mraz, J. Cytochrome P450 1B1: role in health and disease and effect of nutrition on its expression. RSC Adv. 9, 21050\u201321062 (2019).","journal-title":"RSC Adv."},{"key":"11156_CR50","doi-asserted-by":"publisher","first-page":"33101","DOI":"10.1074\/jbc.M011497200","volume":"276","author":"T Baba","year":"2001","unstructured":"Baba, T. et al. Structure and expression of the Ah receptor repressor gene. J. Biol. Chem. 276, 33101\u201333110 (2001).","journal-title":"J. Biol. Chem."},{"key":"11156_CR51","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1042\/BCJ20180347","volume":"475","author":"A Gomez","year":"2018","unstructured":"Gomez, A. et al. Characterization of TCDD-inducible poly-ADP-ribose polymerase (TIPARP\/ARTD14) catalytic activity. Biochem. J. 475, 3827\u20133846 (2018).","journal-title":"Biochem. J."},{"key":"11156_CR52","doi-asserted-by":"crossref","unstructured":"Ishihara, Y., et al. Aryl hydrocarbon receptor signaling synergizes with TLR\/NF-\u03baB-signaling for induction of IL-22 through canonical and non-canonical AhR pathways. Front. Toxicol. Volume 3 - 2021 (2022).","DOI":"10.3389\/ftox.2021.787360"},{"key":"11156_CR53","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1084\/jem.20090560","volume":"206","author":"A Kimura","year":"2009","unstructured":"Kimura, A. et al. Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses. J. Exp. Med. 206, 2027\u20132035 (2009).","journal-title":"J. Exp. Med."},{"key":"11156_CR54","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1476-5926-6-2","volume":"6","author":"AS Mortensen","year":"2007","unstructured":"Mortensen, A. S. & Arukwe, A. Interactions between estrogen- and Ah-receptor signalling pathways in primary culture of salmon hepatocytes exposed to nonylphenol and 3,3\u2019,4,4\u2019-tetrachlorobiphenyl (congener 77). Comp. Hepatol. 6, 2 (2007).","journal-title":"Comp. Hepatol."},{"key":"11156_CR55","doi-asserted-by":"publisher","first-page":"5679517","DOI":"10.1155\/2017\/5679517","volume":"2017","author":"HL Jin","year":"2017","unstructured":"Jin, H. L., Choi, Y. & Jeong, K. W. Crosstalk between aryl hydrocarbon receptor and glucocorticoid receptor in human retinal pigment epithelial cells. Int J. Endocrinol. 2017, 5679517 (2017).","journal-title":"Int J. Endocrinol."},{"key":"11156_CR56","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0083-6729(06)75002-6","volume":"75","author":"KA Murphy","year":"2007","unstructured":"Murphy, K. A., Quadro, L. & White, L. A. The intersection between the aryl hydrocarbon receptor (AhR)- and retinoic acid-signaling pathways. Vitam. Horm. 75, 33\u201367 (2007).","journal-title":"Vitam. Horm."},{"key":"11156_CR57","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.bcp.2008.08.034","volume":"77","author":"F Ohtake","year":"2009","unstructured":"Ohtake, F., Fujii-Kuriyama, Y. & Kato, S. AhR acts as an E3 ubiquitin ligase to modulate steroid receptor functions. Biochem Pharm. 77, 474\u2013484 (2009).","journal-title":"Biochem Pharm."},{"key":"11156_CR58","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/onc.2012.197","volume":"32","author":"C Tomkiewicz","year":"2013","unstructured":"Tomkiewicz, C. et al. The aryl hydrocarbon receptor regulates focal adhesion sites through a non-genomic FAK\/Src pathway. Oncogene 32, 1811\u20131820 (2013).","journal-title":"Oncogene"},{"key":"11156_CR59","doi-asserted-by":"publisher","first-page":"G1006","DOI":"10.1152\/ajpgi.00427.2011","volume":"302","author":"G Xie","year":"2012","unstructured":"Xie, G., Peng, Z. & Raufman, J. P. Src-mediated aryl hydrocarbon and epidermal growth factor receptor cross talk stimulates colon cancer cell proliferation. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G1006\u2013G1015 (2012).","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"11156_CR60","doi-asserted-by":"publisher","first-page":"620270","DOI":"10.3389\/fimmu.2021.620270","volume":"12","author":"H Gro\u00dfkopf","year":"2021","unstructured":"Gro\u00dfkopf, H. et al. Non-genomic AhR-signaling modulates the immune response in endotoxin-activated macrophages after activation by the environmental stressor BaP. Front Immunol. 12, 620270 (2021).","journal-title":"Front Immunol."},{"key":"11156_CR61","doi-asserted-by":"publisher","first-page":"eadn6324","DOI":"10.1126\/scisignal.adn6324","volume":"17","author":"A de Juan","year":"2024","unstructured":"de Juan, A. et al. The aryl hydrocarbon receptor shapes monocyte transcriptional responses to interleukin-4 by prolonging STAT6 binding to promoters. Sci. Signal 17, eadn6324 (2024).","journal-title":"Sci. Signal"},{"key":"11156_CR62","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/biolre\/ioaa128","volume":"103","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Roles of aryl hydrocarbon receptor in endothelial angiogenic responses. Biol. Reprod. 103, 927\u2013937 (2020).","journal-title":"Biol. Reprod."},{"key":"11156_CR63","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1074\/jbc.274.1.510","volume":"274","author":"Y Tian","year":"1999","unstructured":"Tian, Y. et al. Ah receptor and NF-\u03baB interactions, a potential mechanism for dioxin toxicity. J. Biol. Chem. 274, 510\u2013515 (1999).","journal-title":"J. Biol. Chem."},{"key":"11156_CR64","doi-asserted-by":"publisher","first-page":"1277102","DOI":"10.3389\/fimmu.2023.1277102","volume":"14","author":"Y Fu","year":"2023","unstructured":"Fu, Y., Lyu, J. & Wang, S. The role of intestinal microbes on intestinal barrier function and host immunity from a metabolite perspective. Front. Immunol. 14, 1277102 (2023).","journal-title":"Front. Immunol."},{"key":"11156_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51194-w","volume":"9","author":"KM Brawner","year":"2019","unstructured":"Brawner, K. M. et al. Depletion of dietary aryl hydrocarbon receptor ligands alters microbiota composition and function. Sci. Rep. 9, 14724 (2019).","journal-title":"Sci. Rep."},{"key":"11156_CR66","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.3390\/ijms21093189","volume":"21","author":"O Schanz","year":"2020","unstructured":"Schanz, O. et al. Dietary AhR Ligands Regulate AhRR Expression in Intestinal Immune Cells and Intestinal Microbiota Composition. Int. J. Mol. Sci. 21, 3189 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"11156_CR67","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.immuni.2018.07.010","volume":"49","author":"A Metidji","year":"2018","unstructured":"Metidji, A. et al. The environmental sensor AHR protects from inflammatory damage by maintaining intestinal stem cell homeostasis and barrier integrity. Immunity 49, 353\u2013362. e5 (2018).","journal-title":"Immunity"},{"key":"11156_CR68","doi-asserted-by":"publisher","first-page":"19376","DOI":"10.1073\/pnas.2000047117","volume":"117","author":"SA Scott","year":"2020","unstructured":"Scott, S. A., Fu, J. & Chang, P. V. Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor. Proc. Natl. Acad. Sci. 117, 19376\u201319387 (2020).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"11156_CR69","doi-asserted-by":"publisher","first-page":"250225","DOI":"10.5713\/ab.25.0225","volume":"39","author":"D Shi","year":"2025","unstructured":"Shi, D. et al. Gut microbiota-derived tryptophan metabolite indole-3-carboxaldehyde enhances intestinal barrier function via aryl hydrocarbon receptor\/AMP-activated protein kinase signaling activation. Anim. Biosci. 39, 250225 (2025).","journal-title":"Anim. Biosci."},{"key":"11156_CR70","doi-asserted-by":"crossref","unstructured":"Saxena, A. et al. Aryl hydrocarbon receptor regulates Muc2 production independently of IL-22 during Colitis. Int. J. Mol. Sci. 25, 2404 (2024).","DOI":"10.3390\/ijms25042404"},{"key":"11156_CR71","doi-asserted-by":"publisher","first-page":"2377576","DOI":"10.1080\/19490976.2024.2377576","volume":"16","author":"M Li","year":"2024","unstructured":"Li, M. et al. Gut microbiota metabolite indole-3-acetic acid maintains intestinal epithelial homeostasis through mucin sulfation. Gut Microbes 16, 2377576 (2024).","journal-title":"Gut Microbes"},{"key":"11156_CR72","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2011.09.025","volume":"147","author":"Y Li","year":"2011","unstructured":"Li, Y. et al. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell 147, 629\u2013640 (2011).","journal-title":"Cell"},{"key":"11156_CR73","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.immuni.2013.08.002","volume":"39","author":"J Qiu","year":"2013","unstructured":"Qiu, J. et al. Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity 39, 386\u2013399 (2013).","journal-title":"Immunity"},{"key":"11156_CR74","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.immuni.2013.08.003","volume":"39","author":"T Zelante","year":"2013","unstructured":"Zelante, T. et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity 39, 372\u2013385 (2013).","journal-title":"Immunity"},{"key":"11156_CR75","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.chom.2017.06.007","volume":"22","author":"M Wlodarska","year":"2017","unstructured":"Wlodarska, M. et al. Indoleacrylic acid produced by commensal peptostreptococcus species suppresses inflammation. Cell Host Microbe 22, 25\u201337. e6 (2017).","journal-title":"Cell Host Microbe"},{"key":"11156_CR76","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/j.celrep.2019.10.018","volume":"29","author":"CJM Piper","year":"2019","unstructured":"Piper, C. J. M. et al. Aryl hydrocarbon receptor contributes to the transcriptional program of IL-10-producing regulatory B cells. Cell Rep. 29, 1878\u20131892.e7 (2019).","journal-title":"Cell Rep."},{"key":"11156_CR77","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.7150\/thno.95749","volume":"14","author":"Y Gao","year":"2024","unstructured":"Gao, Y. et al. Aryl hydrocarbon receptor confers protection against macrophage pyroptosis and intestinal inflammation through regulating polyamine biosynthesis. Theranostics 14, 4218\u20134239 (2024).","journal-title":"Theranostics"},{"key":"11156_CR78","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1096\/fj.10-169227","volume":"25","author":"X Wang","year":"2011","unstructured":"Wang, X., Hawkins, B. T. & Miller, D. S. Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier. FASEB J. 25, 644\u2013652 (2011).","journal-title":"FASEB J."},{"key":"11156_CR79","doi-asserted-by":"publisher","first-page":"e946","DOI":"10.1212\/NXI.0000000000000946","volume":"8","author":"V Rothhammer","year":"2021","unstructured":"Rothhammer, V. et al. Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS. Neurol. Neuroimmunol. Neuroinflamm. 8, e946 (2021).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"11156_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02764-3","volume":"20","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Microglial aryl hydrocarbon receptor enhances phagocytic function via SYK and promotes remyelination in the cuprizone mouse model of demyelination. J. Neuroinflamm. 20, 83 (2023).","journal-title":"J. Neuroinflamm."},{"key":"11156_CR81","doi-asserted-by":"publisher","first-page":"1618209","DOI":"10.3389\/fncel.2025.1618209","volume":"19","author":"E Ojo","year":"2025","unstructured":"Ojo, E. et al. AhR regulation of amyloid beta-induced inflammation in astrocyte cells. Front Cell Neurosci. 19, 1618209 (2025).","journal-title":"Front Cell Neurosci."},{"key":"11156_CR82","doi-asserted-by":"publisher","first-page":"21000","DOI":"10.1021\/acs.jafc.4c04933","volume":"72","author":"C Wang","year":"2024","unstructured":"Wang, C. et al. Kynurenine attenuates ulcerative colitis mediated by the aryl hydrocarbon receptor. J. Agric. Food Chem. 72, 21000\u201321012 (2024).","journal-title":"J. Agric. Food Chem."},{"key":"11156_CR83","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1007\/s00421-021-04735-z","volume":"121","author":"A Pal","year":"2021","unstructured":"Pal, A. et al. Different endurance exercises modulate NK cell cytotoxic and inhibiting receptors. Eur. J. Appl. Physiol. 121, 3379\u20133387 (2021).","journal-title":"Eur. J. Appl. Physiol."},{"key":"11156_CR84","doi-asserted-by":"publisher","first-page":"e2226","DOI":"10.1002\/brb3.2226","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Tryptophan in the diet ameliorates motor deficits in a rotenone-induced rat Parkinson\u2019s disease model via activating the aromatic hydrocarbon receptor pathway. Brain Behav. 11, e2226 (2021).","journal-title":"Brain Behav."},{"key":"11156_CR85","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.bcp.2019.08.002","volume":"168","author":"E Gonz\u00e1lez-Barbosa","year":"2019","unstructured":"Gonz\u00e1lez-Barbosa, E. et al. Parkin is transcriptionally regulated by the aryl hydrocarbon receptor: Impact on \u03b1-synuclein protein levels. Biochem Pharm. 168, 429\u2013437 (2019).","journal-title":"Biochem Pharm."},{"key":"11156_CR86","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1042\/BCJ20200440","volume":"477","author":"H Park","year":"2020","unstructured":"Park, H. et al. Dopamine is an aryl hydrocarbon receptor agonist. Biochem J. 477, 3899\u20133910 (2020).","journal-title":"Biochem J."},{"key":"11156_CR87","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s42003-026-09561-7","volume":"9","author":"Y Feng","year":"2026","unstructured":"Feng, Y. et al. Gut metabolite indole-3-acetic acid aggravates neuropsychiatric lupus via the AHR\/STAT3 pathway in microglia. Commun. Biol. 9, 281 (2026).","journal-title":"Commun. Biol."},{"key":"11156_CR88","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.brainresbull.2021.08.013","volume":"176","author":"Y Zhou","year":"2021","unstructured":"Zhou, Y. et al. Dynamic changes of activated AHR in microglia and astrocytes in the substantia nigra-striatum system in an MPTP-induced Parkinson\u2019s disease mouse model. Brain Res. Bull. 176, 174\u2013183 (2021).","journal-title":"Brain Res. Bull."},{"key":"11156_CR89","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/glia.22805","volume":"63","author":"YH Lee","year":"2015","unstructured":"Lee, Y. H. et al. Aryl hydrocarbon receptor mediates both proinflammatory and anti-inflammatory effects in lipopolysaccharide-activated microglia. Glia 63, 1138\u20131154 (2015).","journal-title":"Glia"},{"key":"11156_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1572-7","volume":"16","author":"W-C Chen","year":"2019","unstructured":"Chen, W.-C. et al. Aryl hydrocarbon receptor modulates stroke-induced astrogliosis and neurogenesis in the adult mouse brain. J. Neuroinflamm. 16, 187 (2019).","journal-title":"J. Neuroinflamm."},{"key":"11156_CR91","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3389\/fphar.2017.00370","volume":"8","author":"S Adesso","year":"2017","unstructured":"Adesso, S. et al. Indoxyl sulfate affects glial function increasing oxidative stress and neuroinflammation in chronic kidney disease: Interaction between astrocytes and microglia. Front Pharm. 8, 370 (2017).","journal-title":"Front Pharm."},{"key":"11156_CR92","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/nm.4106","volume":"22","author":"V Rothhammer","year":"2016","unstructured":"Rothhammer, V. et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat. Med. 22, 586\u2013597 (2016).","journal-title":"Nat. Med."},{"key":"11156_CR93","doi-asserted-by":"publisher","first-page":"69","DOI":"10.7150\/ijbs.22259","volume":"14","author":"M Yu","year":"2018","unstructured":"Yu, M. et al. Aryl hydrocarbon receptor activation modulates intestinal epithelial barrier function by maintaining tight junction integrity. Int. J. Biol. Sci. 14, 69 (2018).","journal-title":"Int. J. Biol. Sci."},{"key":"11156_CR94","doi-asserted-by":"publisher","first-page":"101007","DOI":"10.1016\/j.molmet.2020.101007","volume":"39","author":"BG Postal","year":"2020","unstructured":"Postal, B. G. et al. AhR activation defends gut barrier integrity against damage occurring in obesity. Mol. Metab. 39, 101007 (2020).","journal-title":"Mol. Metab."},{"key":"11156_CR95","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.bbrc.2019.01.122","volume":"510","author":"K Kurata","year":"2019","unstructured":"Kurata, K. et al. Skatole regulates intestinal epithelial cellular functions through activating aryl hydrocarbon receptors and p38. Biochem Biophys. Res Commun. 510, 649\u2013655 (2019).","journal-title":"Biochem Biophys. Res Commun."},{"key":"11156_CR96","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.3390\/cells13201730","volume":"13","author":"K Ishii","year":"2024","unstructured":"Ishii, K. et al. Molecular mechanisms of skatole-induced inflammatory responses in intestinal epithelial caco-2 cells: Implications for colorectal cancer and inflammatory bowel disease. Cells 13, 1730 (2024).","journal-title":"Cells"},{"key":"11156_CR97","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.aah5825","volume":"357","author":"L Cervantes-Barragan","year":"2017","unstructured":"Cervantes-Barragan, L. et al. Lactobacillus reuteri induces gut intraepithelial CD4(+)CD8\u03b1\u03b1(+) T cells. Science 357, 806\u2013810 (2017).","journal-title":"Science"},{"key":"11156_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-023-01486-1","volume":"11","author":"JS Mar","year":"2023","unstructured":"Mar, J. S. et al. IL-22 alters gut microbiota composition and function to increase aryl hydrocarbon receptor activity in mice and humans. Microbiome 11, 47 (2023).","journal-title":"Microbiome"},{"key":"11156_CR99","doi-asserted-by":"crossref","unstructured":"Zhao, P. et al. Microbial modulation of tryptophan metabolism links gut microbiota to disease and its treatment. Pharmacol. Res. 219, 107896 (2025).","DOI":"10.1016\/j.phrs.2025.107896"},{"key":"11156_CR100","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/microorganisms12020325","volume":"12","author":"J Forero-Rodr\u00edguez","year":"2024","unstructured":"Forero-Rodr\u00edguez, J. et al. Changes in bacterial gut composition in Parkinson\u2019s disease and their metabolic contribution to disease development: A gut community reconstruction approach. Microorganisms 12, 325 (2024).","journal-title":"Microorganisms"},{"key":"11156_CR101","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3390\/applmicrobiol3020030","volume":"3","author":"S Hashish","year":"2023","unstructured":"Hashish, S. & Salama, M. The role of an altered gut microbiome in Parkinson\u2019s disease: A narrative review. Appl. Microbiol. 3, 429\u2013447 (2023).","journal-title":"Appl. Microbiol."},{"key":"11156_CR102","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.bbi.2018.02.005","volume":"70","author":"M-F Sun","year":"2018","unstructured":"Sun, M.-F. et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson\u2019s disease mice: Gut microbiota, glial reaction and TLR4\/TNF-\u03b1 signaling pathway. Brain Behav. Immun. 70, 48\u201360 (2018).","journal-title":"Brain Behav. Immun."},{"key":"11156_CR103","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ana.25982","volume":"89","author":"AH Tan","year":"2021","unstructured":"Tan, A. H. et al. Gut microbial ecosystem in Parkinson disease: New clinicobiological insights from multi-omics. Ann. Neurol. 89, 546\u2013559 (2021).","journal-title":"Ann. Neurol."},{"key":"11156_CR104","doi-asserted-by":"publisher","first-page":"934786","DOI":"10.3389\/fmicb.2022.934786","volume":"13","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Intestinal flora-derived kynurenic acid protects against intestinal damage caused by Candida albicans infection via activation of aryl hydrocarbon receptor. Front. Microbiol. 13, 934786 (2022).","journal-title":"Front. Microbiol."},{"key":"11156_CR105","doi-asserted-by":"publisher","first-page":"1433747","DOI":"10.3389\/fncel.2024.1433747","volume":"18","author":"L Coretti","year":"2024","unstructured":"Coretti, L., Buommino, E. & Lembo, F. The aryl hydrocarbon receptor pathway: a linking bridge between the gut microbiome and neurodegenerative diseases. Front. Cell. Neurosci. 18, 1433747 (2024).","journal-title":"Front. Cell. Neurosci."},{"key":"11156_CR106","doi-asserted-by":"crossref","unstructured":"Cai, J. et al. AS-IV attenuates nigral NLRP3 inflammasome in a Parkinson\u2019s disease mouse model via gut microbiota. Commun Biol. 9, 1197 (2026).","DOI":"10.1038\/s42003-026-10415-5"},{"key":"11156_CR107","doi-asserted-by":"publisher","first-page":"117051","DOI":"10.1016\/j.intimp.2026.117051","volume":"185","author":"H Guo","year":"2026","unstructured":"Guo, H. et al. Lycium ruthenicum Murray anthocyanins alleviate neuroinflammation in MPTP-induced Parkinson\u2019s disease by modulating gut microbiota and tryptophan metabolism. Int. Immunopharmacol. 185, 117051 (2026).","journal-title":"Int. Immunopharmacol."},{"key":"11156_CR108","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3233\/JPD-223179","volume":"12","author":"S-J Chen","year":"2022","unstructured":"Chen, S.-J. et al. Alteration of gut microbial metabolites in the systemic circulation of patients with Parkinson\u2019s disease. J. Parkinson\u2019s. Dis. 12, 1219\u20131230 (2022).","journal-title":"J. Parkinson\u2019s. Dis."},{"key":"11156_CR109","doi-asserted-by":"crossref","unstructured":"Gesper, M. et al. Gut-derived metabolite indole-3-propionic acid modulates mitochondrial function in cardiomyocytes and alters cardiac function. Front. Med. 8, 648259 (2021).","DOI":"10.3389\/fmed.2021.648259"},{"key":"11156_CR110","doi-asserted-by":"publisher","first-page":"9990","DOI":"10.1073\/pnas.152706299","volume":"99","author":"P Andersson","year":"2002","unstructured":"Andersson, P. et al. A constitutively active dioxin\/aryl hydrocarbon receptor induces stomach tumors. Proc. Natl. Acad. Sci. USA 99, 9990\u20139995 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"11156_CR111","doi-asserted-by":"crossref","unstructured":"Zhao, T. et al. Enterococcus hirae QT4713-derived dopamine ameliorates intestinal inflammation and MPTP-induced Parkinson\u2019s disease in mice. npj Parkinson\u2019s Dis. 12, 188 (2026).","DOI":"10.1038\/s41531-026-01392-x"},{"key":"11156_CR112","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.apsb.2025.02.029","volume":"15","author":"M Shang","year":"2025","unstructured":"Shang, M. et al. Microbial metabolite 3-indolepropionic acid alleviated PD pathologies by decreasing enteric glia cell gliosis via suppressing IL-13R\u03b11 related signaling pathways. Acta Pharm. Sin. B 15, 2024\u20132038 (2025).","journal-title":"Acta Pharm. Sin. B"},{"key":"11156_CR113","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/FBP.0000000000000806","volume":"36","author":"CA Madison","year":"2025","unstructured":"Madison, C. A. et al. 1,4-dihydroxy-2-naphthoic acid prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced motor function deficits. Behav. Pharm. 36, 40\u201346 (2025).","journal-title":"Behav. Pharm."},{"key":"11156_CR114","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.3390\/cells10102729","volume":"10","author":"ES Ojo","year":"2021","unstructured":"Ojo, E. S. & Tischkau, S. A. The role of AhR in the hallmarks of brain aging: Friend and foe. Cells 10, 2729 (2021).","journal-title":"Cells"},{"key":"11156_CR115","doi-asserted-by":"publisher","first-page":"117864691769193","DOI":"10.1177\/1178646917691938","volume":"10","author":"AA Badawy","year":"2017","unstructured":"Badawy, A. A. Kynurenine pathway of tryptophan metabolism: Regulatory and functional aspects. Int. J. Tryptophan Res. 10, 1178646917691938 (2017).","journal-title":"Int. J. Tryptophan Res."},{"key":"11156_CR116","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1097\/00001756-200004270-00038","volume":"11","author":"J Urenjak","year":"2000","unstructured":"Urenjak, J. & Obrenovitch, T. P. Neuroprotective potency of kynurenic acid against excitotoxicity. Neuroreport 11, 1341\u20131344 (2000).","journal-title":"Neuroreport"},{"key":"11156_CR117","doi-asserted-by":"publisher","first-page":"S8158","DOI":"10.4137\/IJTR.S8158","volume":"5","author":"VP-D La Cruz","year":"2012","unstructured":"La Cruz, V. P.-D., Carrillo-Mora, P. & Santamar\u00eda, A. Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. Int. J. Tryptophan Res. 5, S8158 (2012). p. IJTR.","journal-title":"Int. J. Tryptophan Res."},{"key":"11156_CR118","doi-asserted-by":"publisher","first-page":"769501","DOI":"10.3389\/fphar.2021.769501","volume":"12","author":"X Li","year":"2021","unstructured":"Li, X. et al. New insights into gut-bacteria-derived indole and its derivatives in intestinal and liver diseases. Front. Pharmacol. 12, 769501 (2021).","journal-title":"Front. Pharmacol."},{"key":"11156_CR119","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.chom.2018.05.003","volume":"23","author":"A Agus","year":"2018","unstructured":"Agus, A., Planchais, J. & Sokol, H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 23, 716\u2013724 (2018).","journal-title":"Cell Host Microbe"},{"key":"11156_CR120","doi-asserted-by":"publisher","first-page":"117864692514014","DOI":"10.1177\/11786469251401459","volume":"18","author":"VA Chakkarwar","year":"2025","unstructured":"Chakkarwar, V. A. & Kulkarni, Y. A. Kynurenine pathway dysregulation in Parkinson\u2019s disease: Insights for disease modulation and therapy. Int. J. Tryptophan Res. 18, 11786469251401459 (2025).","journal-title":"Int. J. Tryptophan Res."},{"key":"11156_CR121","doi-asserted-by":"crossref","unstructured":"Maddison, D.C. and F. Giorgini. The kynurenine pathway and neurodegenerative disease. in Seminars in cell & developmental biology. Elsevier (2015).","DOI":"10.1016\/j.semcdb.2015.03.002"},{"key":"11156_CR122","doi-asserted-by":"publisher","first-page":"110797","DOI":"10.1016\/j.exger.2019.110797","volume":"130","author":"H Kaiser","year":"2020","unstructured":"Kaiser, H., Parker, E. & Hamrick, M. W. Kynurenine signaling through the aryl hydrocarbon receptor: Implications for aging and healthspan. Exp. Gerontol. 130, 110797 (2020).","journal-title":"Exp. Gerontol."},{"key":"11156_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/srep12689","volume":"5","author":"TD Hubbard","year":"2015","unstructured":"Hubbard, T. D. et al. Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles. Sci. Rep. 5, 12689 (2015).","journal-title":"Sci. Rep."},{"key":"11156_CR124","doi-asserted-by":"publisher","first-page":"1859812","DOI":"10.1080\/19490976.2020.1859812","volume":"12","author":"F Dong","year":"2020","unstructured":"Dong, F. & Perdew, G. H. The aryl hydrocarbon receptor as a mediator of host-microbiota interplay. Gut Microbes 12, 1859812 (2020).","journal-title":"Gut Microbes"},{"key":"11156_CR125","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41577-019-0125-8","volume":"19","author":"V Rothhammer","year":"2019","unstructured":"Rothhammer, V. & Quintana, F. J. The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease. Nat. Rev. Immunol. 19, 184\u2013197 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"11156_CR126","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1007\/s00204-017-1981-2","volume":"91","author":"SK Kolluri","year":"2017","unstructured":"Kolluri, S. K., Jin, U.-H. & Safe, S. Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target. Arch. Toxicol. 91, 2497\u20132513 (2017).","journal-title":"Arch. Toxicol."},{"key":"11156_CR127","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.3390\/ijms19123851","volume":"19","author":"DR Neavin","year":"2018","unstructured":"Neavin, D. R. et al. The role of the aryl hydrocarbon receptor (AHR) in immune and inflammatory diseases. Int. J. Mol. Sci. 19, 3851 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"11156_CR128","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3390\/cells9071687","volume":"9","author":"M Pajares","year":"2020","unstructured":"Pajares, M. et al. Inflammation in Parkinson\u2019s disease: Mechanisms and therapeutic implications. Cells 9, 1687 (2020).","journal-title":"Cells"},{"key":"11156_CR129","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.1007\/s12035-017-0845-3","volume":"55","author":"K-H Chang","year":"2018","unstructured":"Chang, K.-H. et al. Alternations of metabolic profile and kynurenine metabolism in the plasma of Parkinson\u2019s disease. Mol. Neurobiol. 55, 6319\u20136328 (2018).","journal-title":"Mol. Neurobiol."},{"key":"11156_CR130","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s42003-019-0520-5","volume":"2","author":"S Zhang","year":"2019","unstructured":"Zhang, S. et al. A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites. Commun. Biol. 2, 271 (2019).","journal-title":"Commun. Biol."},{"key":"11156_CR131","doi-asserted-by":"publisher","first-page":"134576","DOI":"10.1016\/j.neulet.2019.134576","volume":"714","author":"K Iwaoka","year":"2020","unstructured":"Iwaoka, K. et al. Impaired metabolism of kynurenine and its metabolites in CSF of parkinson\u2019s disease. Neurosci. Lett. 714, 134576 (2020).","journal-title":"Neurosci. Lett."},{"key":"11156_CR132","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jns.2009.02.326","volume":"283","author":"E Vamos","year":"2009","unstructured":"Vamos, E. et al. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. J. Neurol. Sci. 283, 21\u201327 (2009).","journal-title":"J. Neurol. Sci."},{"key":"11156_CR133","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1007\/s12035-023-03815-9","volume":"61","author":"HWS Babu","year":"2024","unstructured":"Babu, H. W. S. et al. Association Study Between Kynurenine 3-Monooxygenase (KMO) Gene and Parkinson\u2019s Disease Patients. Mol. Neurobiol. 61, 3867\u20133881 (2024).","journal-title":"Mol. Neurobiol."},{"key":"11156_CR134","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1074\/jbc.RA117.000631","volume":"293","author":"SH Seok","year":"2018","unstructured":"Seok, S. H. et al. Trace derivatives of kynurenine potently activate the aryl hydrocarbon receptor (AHR). J. Biol. Chem. 293, 1994\u20132005 (2018).","journal-title":"J. Biol. Chem."},{"key":"11156_CR135","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41564-024-01737-3","volume":"9","author":"AK Sinha","year":"2024","unstructured":"Sinha, A. K. et al. Dietary fibre directs microbial tryptophan metabolism via metabolic interactions in the gut microbiota. Nat. Microbiol. 9, 1964\u20131978 (2024).","journal-title":"Nat. Microbiol."},{"key":"11156_CR136","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1021\/jm00031a015","volume":"37","author":"R Pellicciari","year":"1994","unstructured":"Pellicciari, R. et al. Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase. J. Med Chem. 37, 647\u2013655 (1994).","journal-title":"J. Med Chem."},{"key":"11156_CR137","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.cell.2011.05.020","volume":"145","author":"D Zwilling","year":"2011","unstructured":"Zwilling, D. et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145, 863\u2013874 (2011).","journal-title":"Cell"},{"key":"11156_CR138","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cub.2011.04.028","volume":"21","author":"S Campesan","year":"2011","unstructured":"Campesan, S. et al. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington\u2019s disease. Curr. Biol. 21, 961\u2013966 (2011).","journal-title":"Curr. Biol."},{"key":"11156_CR139","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41531-025-00964-7","volume":"11","author":"EN Wilson","year":"2025","unstructured":"Wilson, E. N. et al. Parkinson\u2019s disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction. npj Parkinson\u2019s. Dis. 11, 96 (2025).","journal-title":"npj Parkinson\u2019s. Dis."},{"key":"11156_CR140","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s007020200014","volume":"109","author":"B Widner","year":"2002","unstructured":"Widner, B., Leblhuber, F. & Fuchs, D. Increased neopterin production and tryptophan degradation in advanced Parkinson\u2019s disease. J. Neural Transm. 109, 181\u2013189 (2002).","journal-title":"J. Neural Transm."},{"key":"11156_CR141","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1002\/mds.28202","volume":"35","author":"PL Heilman","year":"2020","unstructured":"Heilman, P. L. et al. Tryptophan metabolites are associated with symptoms and nigral pathology in Parkinson\u2019s disease. Mov. Disord. 35, 2028\u20132037 (2020).","journal-title":"Mov. Disord."},{"key":"11156_CR142","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10072-020-04589-x","volume":"42","author":"J-H Bai","year":"2021","unstructured":"Bai, J.-H., Zheng, Y.-L. & Yu, Y.-P. Urinary kynurenine as a biomarker for Parkinson\u2019s disease. Neurol. Sci. 42, 697\u2013703 (2021).","journal-title":"Neurol. Sci."},{"key":"11156_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/srep13888","volume":"5","author":"H Luan","year":"2015","unstructured":"Luan, H. et al. Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson\u2019s disease. Sci. Rep. 5, 13888 (2015).","journal-title":"Sci. Rep."},{"key":"11156_CR144","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41531-021-00239-x","volume":"7","author":"S Klatt","year":"2021","unstructured":"Klatt, S. et al. A six-metabolite panel as potential blood-based biomarkers for Parkinson\u2019s disease. npj Parkinson\u2019s. Dis. 7, 94 (2021).","journal-title":"npj Parkinson\u2019s. Dis."},{"key":"11156_CR145","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1212\/WNL.42.9.1702","volume":"42","author":"T Ogawa","year":"1992","unstructured":"Ogawa, T. et al. Kynurenine pathway abnormalities in Parkinson\u2019s disease. Neurology 42, 1702\u20131702 (1992).","journal-title":"Neurology"},{"key":"11156_CR146","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41531-025-00949-6","volume":"11","author":"LC Jellen","year":"2025","unstructured":"Jellen, L. C. et al. Sex differences in peripheral and central dysregulation of the kynurenine pathway in Parkinson\u2019s disease. NPJ Parkinsons Dis. 11, 116 (2025).","journal-title":"NPJ Parkinsons Dis."},{"key":"11156_CR147","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/0022-510X(92)90191-M","volume":"108","author":"MF Beal","year":"1992","unstructured":"Beal, M. F. et al. Kynurenic acid concentrations are reduced in Huntington\u2019s disease cerebral cortex. J. Neurol. Sci. 108, 80\u201387 (1992).","journal-title":"J. Neurol. Sci."},{"key":"11156_CR148","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1021\/pr500807t","volume":"14","author":"H Luan","year":"2015","unstructured":"Luan, H. et al. LC-MS-based urinary metabolite signatures in idiopathic Parkinson\u2019s disease. J. Proteome Res 14, 467\u2013478 (2015).","journal-title":"J. Proteome Res"},{"key":"11156_CR149","doi-asserted-by":"crossref","unstructured":"Chung, S.H. et al. Profiling analysis of tryptophan metabolites in the urine of patients with Parkinson\u2019s disease using LC-MS\/MS. Pharmaceuticals (Basel) 16, 1495 (2023).","DOI":"10.3390\/ph16101495"},{"key":"11156_CR150","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1038\/npp.2010.39","volume":"35","author":"MC Potter","year":"2010","unstructured":"Potter, M. C. et al. Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 35, 1734\u20131742 (2010).","journal-title":"Neuropsychopharmacology"},{"key":"11156_CR151","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ntt.2010.10.002","volume":"33","author":"D Silva-Adaya","year":"2011","unstructured":"Silva-Adaya, D. et al. Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy. Neurotoxicol Teratol. 33, 303\u2013312 (2011).","journal-title":"Neurotoxicol Teratol."},{"key":"11156_CR152","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/mds.25555","volume":"28","author":"PA Lewitt","year":"2013","unstructured":"Lewitt, P. A. et al. 3-hydroxykynurenine and other Parkinson\u2019s disease biomarkers discovered by metabolomic analysis. Mov. Disord. 28, 1653\u20131660 (2013).","journal-title":"Mov. Disord."},{"key":"11156_CR153","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/jnc.14843","volume":"151","author":"FJH Sorgdrager","year":"2019","unstructured":"Sorgdrager, F. J. H. et al. Age- and disease-specific changes of the kynurenine pathway in Parkinson\u2019s and Alzheimer\u2019s disease. J. Neurochem 151, 656\u2013668 (2019).","journal-title":"J. Neurochem"},{"key":"11156_CR154","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0006-8993(83)90993-9","volume":"275","author":"B Scatton","year":"1983","unstructured":"Scatton, B. et al. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson\u2019s disease. Brain Res. 275, 321\u2013328 (1983).","journal-title":"Brain Res"},{"key":"11156_CR155","first-page":"120","volume":"131","author":"SJ Kish","year":"2008","unstructured":"Kish, S. J. et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson\u2019s disease. Brain 131, 120\u2013131 (2008).","journal-title":"Brain"},{"key":"11156_CR156","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1093\/brain\/awv215","volume":"138","author":"Z Qamhawi","year":"2015","unstructured":"Qamhawi, Z. et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson\u2019s disease. Brain 138, 2964\u20132973 (2015).","journal-title":"Brain"},{"key":"11156_CR157","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1172\/JCI71640","volume":"124","author":"M Politis","year":"2014","unstructured":"Politis, M. et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson\u2019s disease patients. J. Clin. Invest 124, 1340\u20131349 (2014).","journal-title":"J. Clin. Invest"},{"key":"11156_CR158","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1093\/brain\/aww162","volume":"139","author":"A Maillet","year":"2016","unstructured":"Maillet, A. et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson\u2019s disease. Brain 139, 2486\u20132502 (2016).","journal-title":"Brain"},{"key":"11156_CR159","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3233\/JPD-223165","volume":"12","author":"N Radisavljevic","year":"2022","unstructured":"Radisavljevic, N. et al. Effects of gut microbiota alterations on motor, gastrointestinal, and behavioral phenotype in a mouse model of Parkinson\u2019s disease. J. Parkinsons Dis. 12, 1479\u20131495 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"11156_CR160","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41531-023-00612-y","volume":"9","author":"S-J Chen","year":"2023","unstructured":"Chen, S.-J. et al. Plasma metabolites of aromatic amino acids associate with clinical severity and gut microbiota of Parkinson\u2019s disease. npj Parkinson\u2019s. Dis. 9, 165 (2023).","journal-title":"npj Parkinson\u2019s. Dis."},{"key":"11156_CR161","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.parkreldis.2015.02.004","volume":"21","author":"E Cassani","year":"2015","unstructured":"Cassani, E. et al. Increased urinary indoxyl sulfate (indican): New insights into gut dysbiosis in Parkinson\u2019s disease. Parkinsonism Relat. Disord. 21, 389\u2013393 (2015).","journal-title":"Parkinsonism Relat. Disord."},{"key":"11156_CR162","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00425-8","volume":"16","author":"Y Shao","year":"2021","unstructured":"Shao, Y. et al. Comprehensive metabolic profiling of Parkinson\u2019s disease by liquid chromatography-mass spectrometry. Mol. Neurodegener. 16, 4 (2021).","journal-title":"Mol. Neurodegener."},{"key":"11156_CR163","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41392-026-02613-8","volume":"11","author":"Y Shao","year":"2026","unstructured":"Shao, Y. et al. Distinct metabolomic and proteomic signatures in Parkinson\u2019s disease patients with REM sleep behavior disorder. Signal Transduct. Target. Ther. 11, 115 (2026).","journal-title":"Signal Transduct. Target. Ther."},{"key":"11156_CR164","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nm.4102","volume":"22","author":"B Lamas","year":"2016","unstructured":"Lamas, B. et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat. Med 22, 598\u2013605 (2016).","journal-title":"Nat. Med"},{"key":"11156_CR165","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.cmet.2018.07.001","volume":"28","author":"JM Natividad","year":"2018","unstructured":"Natividad, J. M. et al. Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. Cell Metab. 28, 737\u2013749.e4 (2018).","journal-title":"Cell Metab."},{"key":"11156_CR166","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S0006-8993(98)01027-0","volume":"815","author":"B Poeggeler","year":"1999","unstructured":"Poeggeler, B. et al. Indole-3-propionate: A potent hydroxyl radical scavenger in rat brain. Brain Res. 815, 382\u2013388 (1999).","journal-title":"Brain Res"},{"key":"11156_CR167","doi-asserted-by":"publisher","first-page":"21937","DOI":"10.1074\/jbc.274.31.21937","volume":"274","author":"Y-J Chyan","year":"1999","unstructured":"Chyan, Y.-J. et al. Potent neuroprotective properties against the Alzheimer \u03b2-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid *. J. Biol. Chem. 274, 21937\u201321942 (1999).","journal-title":"J. Biol. Chem."},{"key":"11156_CR168","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12015","volume":"7","author":"S Jangi","year":"2016","unstructured":"Jangi, S. et al. Alterations of the human gut microbiome in multiple sclerosis. Nat. Commun. 7, 12015 (2016).","journal-title":"Nat. Commun."},{"key":"11156_CR169","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57400-8","volume":"14","author":"T Zelante","year":"2024","unstructured":"Zelante, T. et al. A microbially produced AhR ligand promotes a Tph1-driven tolerogenic program in multiple sclerosis. Sci. Rep. 14, 6651 (2024).","journal-title":"Sci. Rep."},{"key":"11156_CR170","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.3390\/foods13213479","volume":"13","author":"A De la Rosa Gonz\u00e1lez","year":"2024","unstructured":"De la Rosa Gonz\u00e1lez, A. et al. Effect of probiotics on gastrointestinal health through the aryl hydrocarbon receptor pathway: A systematic review. Foods 13, 3479 (2024).","journal-title":"Foods"},{"key":"11156_CR171","doi-asserted-by":"publisher","first-page":"eaba0624","DOI":"10.1126\/scitranslmed.aba0624","volume":"12","author":"B Lamas","year":"2020","unstructured":"Lamas, B. et al. Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation. Sci. Transl. Med. 12, eaba0624 (2020).","journal-title":"Sci. Transl. Med."},{"key":"11156_CR172","doi-asserted-by":"crossref","unstructured":"Lano, G., Burtey, S. & Sall\u00e9e M. Indoxyl sulfate, a uremic endotheliotoxin. Toxins (Basel) 12, 229 (2020).","DOI":"10.3390\/toxins12040229"},{"key":"11156_CR173","doi-asserted-by":"publisher","first-page":"126181","DOI":"10.1016\/j.jhazmat.2021.126181","volume":"416","author":"Q Ma","year":"2021","unstructured":"Ma, Q. et al. Occurrence, impacts, and microbial transformation of 3-methylindole (skatole): A critical review. J. Hazard. Mater. 416, 126181 (2021).","journal-title":"J. Hazard. Mater."},{"key":"11156_CR174","doi-asserted-by":"publisher","first-page":"e70574","DOI":"10.1096\/fj.202500295R","volume":"39","author":"N Shaheen","year":"2025","unstructured":"Shaheen, N. et al. Multifaceted role of microbiota-derived indole-3-acetic acid in human diseases and its potential clinical application. FASEB J. 39, e70574 (2025).","journal-title":"FASEB J."},{"key":"11156_CR175","doi-asserted-by":"crossref","unstructured":"Cheng, T.H. et al. Indoxyl sulfate, a tubular toxin, contributes to the development of chronic kidney disease. Toxins (Basel) 12, 684 (2020).","DOI":"10.3390\/toxins12110684"},{"key":"11156_CR176","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03130-z","volume":"7","author":"HY Kim","year":"2017","unstructured":"Kim, H. Y. et al. Indoxyl sulfate (IS)-mediated immune dysfunction provokes endothelial damage in patients with end-stage renal disease (ESRD). Sci. Rep. 7, 3057 (2017).","journal-title":"Sci. Rep."},{"key":"11156_CR177","doi-asserted-by":"crossref","unstructured":"Effects of indoxyl sulfate on dopaminergic neurons and motor functions. J. Pharmaceutical Negative Results 11, 30\u201334 (2020).","DOI":"10.4103\/jpnr.JPNR_23_19"},{"key":"11156_CR178","doi-asserted-by":"publisher","first-page":"997240","DOI":"10.3389\/fimmu.2022.997240","volume":"13","author":"M Fathi","year":"2022","unstructured":"Fathi, M. et al. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer\u2019s disease, Parkinson\u2019s disease, and Huntington\u2019s disease: A systematic Review and meta-analysis. Front. Immunol. 13, 997240 (2022).","journal-title":"Front. Immunol."},{"key":"11156_CR179","doi-asserted-by":"crossref","unstructured":"Zinger, A. et al. The involvement of neuroinflammation and kynurenine pathway in Parkinson\u2032 s disease. Parkinson\u2019s Dis. 2011:716859 (2011).","DOI":"10.4061\/2011\/716859"},{"key":"11156_CR180","doi-asserted-by":"publisher","first-page":"100270","DOI":"10.1016\/j.ensci.2020.100270","volume":"21","author":"D Venkatesan","year":"2020","unstructured":"Venkatesan, D. et al. Kynurenine pathway in Parkinson\u2019s disease-An update. eNeurologicalSci 21, 100270 (2020).","journal-title":"eNeurologicalSci"},{"key":"11156_CR181","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.parkreldis.2019.06.003","volume":"65","author":"D Pietrucci","year":"2019","unstructured":"Pietrucci, D. et al. Dysbiosis of gut microbiota in a selected population of Parkinson\u2019s patients. Parkinsonism Relat. Disord. 65, 124\u2013130 (2019).","journal-title":"Parkinsonism Relat. Disord."},{"key":"11156_CR182","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/mds.26942","volume":"32","author":"EM Hill-Burns","year":"2017","unstructured":"Hill-Burns, E. M. et al. Parkinson\u2019s disease and Parkinson\u2019s disease medications have distinct signatures of the gut microbiome. Mov. Disord. 32, 739\u2013749 (2017).","journal-title":"Mov. Disord."},{"key":"11156_CR183","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34667-x","volume":"13","author":"ZD Wallen","year":"2022","unstructured":"Wallen, Z. D. et al. Metagenomics of Parkinson\u2019s disease implicates the gut microbiome in multiple disease mechanisms. Nat. Commun. 13, 6958 (2022).","journal-title":"Nat. Commun."},{"key":"11156_CR184","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00427-6","volume":"16","author":"VT Aho","year":"2021","unstructured":"Aho, V. T. et al. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson\u2019s disease. Mol. Neurodegener. 16, 6 (2021).","journal-title":"Mol. Neurodegener."},{"key":"11156_CR185","doi-asserted-by":"publisher","first-page":"e848","DOI":"10.1212\/WNL.0000000000013225","volume":"98","author":"S-J Chen","year":"2022","unstructured":"Chen, S.-J. et al. Association of fecal and plasma levels of short-chain fatty acids with gut microbiota and clinical severity in patients with Parkinson disease. Neurology 98, e848\u2013e858 (2022).","journal-title":"Neurology"},{"key":"11156_CR186","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/gutjnl-2018-316844","volume":"68","author":"P Perez-Pardo","year":"2019","unstructured":"Perez-Pardo, P. et al. Role of TLR4 in the gut-brain axis in Parkinson\u2019s disease: a translational study from men to mice. Gut 68, 829\u2013843 (2019).","journal-title":"Gut"},{"key":"11156_CR187","doi-asserted-by":"publisher","first-page":"e53111","DOI":"10.7554\/eLife.53111","volume":"9","author":"TR Sampson","year":"2020","unstructured":"Sampson, T. R. et al. A gut bacterial amyloid promotes \u03b1-synuclein aggregation and motor impairment in mice. eLife 9, e53111 (2020).","journal-title":"eLife"},{"key":"11156_CR188","doi-asserted-by":"publisher","first-page":"839","DOI":"10.3389\/fnins.2019.00839","volume":"13","author":"AM Gorecki","year":"2019","unstructured":"Gorecki, A. M. et al. Altered gut microbiome in Parkinson\u2019s disease and the influence of lipopolysaccharide in a human \u03b1-synuclein over-expressing mouse model. Front Neurosci. 13, 839 (2019).","journal-title":"Front Neurosci."},{"key":"11156_CR189","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.brainres.2017.04.019","volume":"1667","author":"F Hopfner","year":"2017","unstructured":"Hopfner, F. et al. Gut microbiota in Parkinson disease in a northern German cohort. Brain Res. 1667, 41\u201345 (2017).","journal-title":"Brain Res."},{"key":"11156_CR190","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s10517-017-3700-7","volume":"162","author":"VA Petrov","year":"2017","unstructured":"Petrov, V. A. et al. Analysis of gut microbiota in patients with Parkinson\u2019s disease. Bull. Exp. Biol. Med 162, 734\u2013737 (2017).","journal-title":"Bull. Exp. Biol. Med"},{"key":"11156_CR191","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/mds.27581","volume":"34","author":"M Barichella","year":"2019","unstructured":"Barichella, M. et al. Unraveling gut microbiota in Parkinson\u2019s disease and atypical parkinsonism. Mov. Disord. 34, 396\u2013405 (2019).","journal-title":"Mov. Disord."},{"key":"11156_CR192","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.3233\/JPD-223500","volume":"12","author":"K Zhang","year":"2022","unstructured":"Zhang, K. et al. Parkinson\u2019s disease and the gut microbiome in rural California. J. Parkinson\u2019s. Dis. 12, 2441\u20132452 (2022).","journal-title":"J. Parkinson\u2019s. Dis."},{"key":"11156_CR193","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41531-019-0100-x","volume":"5","author":"S Weis","year":"2019","unstructured":"Weis, S. et al. Effect of Parkinson\u2019s disease and related medications on the composition of the fecal bacterial microbiota. npj Parkinson\u2019s. Dis. 5, 28 (2019).","journal-title":"npj Parkinson\u2019s. Dis."},{"key":"11156_CR194","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.ebiom.2019.05.064","volume":"44","author":"VTE Aho","year":"2019","unstructured":"Aho, V. T. E. et al. Gut microbiota in Parkinson\u2019s disease: Temporal stability and relations to disease progression. EBioMedicine 44, 691\u2013707 (2019).","journal-title":"EBioMedicine"},{"key":"11156_CR195","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.3390\/nu14214678","volume":"14","author":"T Li","year":"2022","unstructured":"Li, T. et al. Neuroprotective effects of bifidobacterium breve CCFM1067 in MPTP-induced mouse models of Parkinson\u2019s disease. Nutrients 14, 4678 (2022).","journal-title":"Nutrients"},{"key":"11156_CR196","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/mds.26069","volume":"30","author":"F Scheperjans","year":"2015","unstructured":"Scheperjans, F. et al. Gut microbiota are related to Parkinson\u2019s disease and clinical phenotype. Mov. Disord. 30, 350\u2013358 (2015).","journal-title":"Mov. Disord."},{"key":"11156_CR197","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13073-017-0428-y","volume":"9","author":"JR Bedarf","year":"2017","unstructured":"Bedarf, J. R. et al. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-na\u00efve Parkinson\u2019s disease patients. Genome Med. 9, 1\u201313 (2017).","journal-title":"Genome Med."},{"key":"11156_CR198","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41531-022-00328-5","volume":"8","author":"H Nishiwaki","year":"2022","unstructured":"Nishiwaki, H. et al. Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson\u2019s disease. NPJ Parkinsons Dis. 8, 65 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"11156_CR199","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/brainsci14030238","volume":"14","author":"C-M Qiao","year":"2024","unstructured":"Qiao, C.-M. et al. Akkermansia muciniphila is beneficial to a mouse model of Parkinson\u2019s disease, via alleviated neuroinflammation and promoted neurogenesis, with involvement of SCFAs. Brain Sci. 14, 238 (2024).","journal-title":"Brain Sci."},{"key":"11156_CR200","doi-asserted-by":"publisher","first-page":"103908","DOI":"10.1016\/j.isci.2022.103908","volume":"25","author":"DP Amorim Neto","year":"2022","unstructured":"Amorim Neto, D. P. et al. Akkermansia muciniphila induces mitochondrial calcium overload and \u03b1 -synuclein aggregation in an enteroendocrine cell line. iScience 25, 103908 (2022).","journal-title":"iScience"},{"key":"11156_CR201","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1099\/ijs.0.02873-0","volume":"54","author":"M Derrien","year":"2004","unstructured":"Derrien, M. et al. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J. Syst. Evol. Microbiol 54, 1469\u20131476 (2004).","journal-title":"Int J. Syst. Evol. Microbiol"},{"key":"11156_CR202","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/mds.28052","volume":"35","author":"MS Cirstea","year":"2020","unstructured":"Cirstea, M. S. et al. Microbiota composition and metabolism are associated with gut function in Parkinson\u2019s disease. Mov. Disord. 35, 1208\u20131217 (2020).","journal-title":"Mov. Disord."},{"key":"11156_CR203","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41531-026-01287-x","volume":"12","author":"A Moiseyenko","year":"2026","unstructured":"Moiseyenko, A. et al. Faecalibacterium prausnitzii, depleted in the Parkinson\u2019s disease microbiome, improves motor deficits in \u03b1-synuclein overexpressing mice. npj Parkinson\u2019s. Dis. 12, 94 (2026).","journal-title":"npj Parkinson\u2019s. Dis."},{"key":"11156_CR204","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbi.2022.08.003","volume":"106","author":"J Sun","year":"2022","unstructured":"Sun, J. et al. Microbiota-derived metabolite Indoles induced aryl hydrocarbon receptor activation and inhibited neuroinflammation in APP\/PS1 mice. Brain, Behav., Immun. 106, 76\u201388 (2022).","journal-title":"Brain, Behav., Immun."},{"key":"11156_CR205","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.bbi.2024.08.051","volume":"122","author":"H Kim","year":"2024","unstructured":"Kim, H. et al. Microbiome-derived indole-3-lactic acid reduces amyloidopathy through aryl-hydrocarbon receptor activation. Brain, Behav., Immun. 122, 568\u2013582 (2024).","journal-title":"Brain, Behav., Immun."},{"key":"11156_CR206","doi-asserted-by":"publisher","first-page":"153331752312148","DOI":"10.1177\/15333175231214861","volume":"38","author":"Z Duan","year":"2023","unstructured":"Duan, Z. et al. The protective effect of IDO1 inhibition in A\u03b2-treated neurons and APP\/PS1 mice. Am. J. Alzheimer\u2019s. Dis. Other Dement. \u00ae 38, 15333175231214861 (2023).","journal-title":"Am. J. Alzheimer\u2019s. Dis. Other Dement. \u00ae"},{"key":"11156_CR207","doi-asserted-by":"publisher","first-page":"113230","DOI":"10.1016\/j.bbr.2021.113230","volume":"408","author":"QD Angeles-L\u00f3pez","year":"2021","unstructured":"Angeles-L\u00f3pez, Q. D. et al. The absence of the aryl hydrocarbon receptor in the R6\/1 transgenic mouse model of Huntington\u2019s disease improves the neurological phenotype. Behav. Brain Res. 408, 113230 (2021).","journal-title":"Behav. Brain Res."},{"key":"11156_CR208","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-017-0177-9","volume":"12","author":"PE Ash","year":"2017","unstructured":"Ash, P. E. et al. Dioxins and related environmental contaminants increase TDP-43 levels. Mol. Neurodegener. 12, 35 (2017).","journal-title":"Mol. Neurodegener."},{"key":"11156_CR209","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1161\/CIRCULATIONAHA.114.011394","volume":"130","author":"MI Cuartero","year":"2014","unstructured":"Cuartero, M. I. et al. L-kynurenine\/aryl hydrocarbon receptor pathway mediates brain damage after experimental stroke. Circulation 130, 2040\u20132051 (2014).","journal-title":"Circulation"},{"key":"11156_CR210","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3390\/cells10040718","volume":"10","author":"M Tanaka","year":"2021","unstructured":"Tanaka, M. et al. Involvement of the microglial aryl hydrocarbon receptor in neuroinflammation and vasogenic edema after ischemic stroke. Cells 10, 718 (2021).","journal-title":"Cells"},{"key":"11156_CR211","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57014-2","volume":"16","author":"P Peesh","year":"2025","unstructured":"Peesh, P. et al. Benefits of equilibrium between microbiota-and host-derived ligands of the aryl hydrocarbon receptor after stroke in aged male mice. Nat. Commun. 16, 1767 (2025).","journal-title":"Nat. Commun."},{"key":"11156_CR212","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-017-0056-8","volume":"8","author":"D Liu","year":"2018","unstructured":"Liu, D. et al. Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics. Transl. Psychiatry 8, 10 (2018).","journal-title":"Transl. Psychiatry"},{"key":"11156_CR213","first-page":"353","volume":"76","author":"MY Wang","year":"2024","unstructured":"Wang, M. Y. et al. Activation of aryl hydrocarbon receptor (AhR) alleviates depressive-like behaviors in LPS-induced mice. Sheng Li Xue Bao 76, 353\u2013364 (2024).","journal-title":"Sheng Li Xue Bao"},{"key":"11156_CR214","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1001\/jamaneurol.2024.2305","volume":"81","author":"F Scheperjans","year":"2024","unstructured":"Scheperjans, F. et al. Fecal microbiota transplantation for treatment of Parkinson disease: A randomized clinical trial. JAMA Neurol. 81, 925\u2013938 (2024).","journal-title":"JAMA Neurol."},{"key":"11156_CR215","doi-asserted-by":"publisher","first-page":"1104759","DOI":"10.3389\/fneur.2023.1104759","volume":"14","author":"HL DuPont","year":"2023","unstructured":"DuPont, H. L. et al. Fecal microbiota transplantation in Parkinson\u2019s disease\u2014A randomized repeat-dose, placebo-controlled clinical pilot study. Front. Neurol. 14, 1104759 (2023).","journal-title":"Front. Neurol."},{"key":"11156_CR216","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41531-025-01061-5","volume":"11","author":"M De Sciscio","year":"2025","unstructured":"De Sciscio, M. et al. Faecal microbiota transplant in Parkinson\u2019s disease: Pilot study to establish safety & tolerability. npj Parkinson\u2019s. Dis. 11, 203 (2025).","journal-title":"npj Parkinson\u2019s. Dis."},{"key":"11156_CR217","doi-asserted-by":"publisher","first-page":"1496616","DOI":"10.3389\/fnut.2024.1496616","volume":"11","author":"M Alam","year":"2024","unstructured":"Alam, M. et al. Microbiome-based therapies for Parkinson\u2019s disease. Front. Nutr. 11, 1496616 (2024).","journal-title":"Front. Nutr."},{"key":"11156_CR218","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.3390\/biomedicines12122912","volume":"12","author":"F-C Huang","year":"2024","unstructured":"Huang, F.-C. Therapeutic potential of nutritional aryl hydrocarbon receptor ligands in gut-related inflammation and diseases. Biomedicines 12, 2912 (2024).","journal-title":"Biomedicines"},{"key":"11156_CR219","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/ph15030336","volume":"15","author":"M Puccetti","year":"2022","unstructured":"Puccetti, M. et al. Pharmaceutically active microbial AhR agonists as innovative biodrugs in inflammation. Pharmaceuticals 15, 336 (2022).","journal-title":"Pharmaceuticals"},{"key":"11156_CR220","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41531-023-00541-w","volume":"9","author":"C Rusch","year":"2023","unstructured":"Rusch, C. et al. To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson\u2019s disease. NPJ Parkinsons Dis. 9, 98 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"11156_CR221","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.2174\/1570159X19666211116142806","volume":"20","author":"W Agnieszka","year":"2022","unstructured":"Agnieszka, W., Pawe\u0142, P. & Ma\u0142gorzata, K. How to optimize the effectiveness and safety of Parkinson\u2019s disease therapy? - A systematic review of drugs interactions with food and dietary supplements. Curr. Neuropharmacol. 20, 1427\u20131447 (2022).","journal-title":"Curr. Neuropharmacol."},{"key":"11156_CR222","doi-asserted-by":"crossref","unstructured":"Ghezzi, L. et al. Targeting the gut to treat multiple sclerosis. J. Clin. Invest. 131, e143774 (2021).","DOI":"10.1172\/JCI143774"},{"key":"11156_CR223","doi-asserted-by":"crossref","unstructured":"Fontana, L. et al. Effects of dietary restriction on neuroinflammation in neurodegenerative diseases. J. Exp. Med. 218, e20190086 (2021).","DOI":"10.1084\/jem.20190086"},{"key":"11156_CR224","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.cmet.2018.05.006","volume":"27","author":"F Cignarella","year":"2018","unstructured":"Cignarella, F. et al. Intermittent fasting confers protection in CNS autoimmunity by altering the gut microbiota. Cell Metab. 27, 1222\u20131235.e6 (2018).","journal-title":"Cell Metab."},{"key":"11156_CR225","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.celrep.2016.05.009","volume":"15","author":"IY Choi","year":"2016","unstructured":"Choi, I. Y. et al. A diet mimicking fasting promotes regeneration and reduces autoimmunity and multiple sclerosis symptoms. Cell Rep. 15, 2136\u20132146 (2016).","journal-title":"Cell Rep."},{"key":"11156_CR226","doi-asserted-by":"crossref","unstructured":"Haupt, J. et al. Novel aryl hydrocarbon receptor agonists as potential anti-inflammatory therapeutics: Identification and validation through drug repurposing. Biochem. Pharmacol. 240, 117066 (2025).","DOI":"10.1016\/j.bcp.2025.117066"},{"key":"11156_CR227","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3390\/pharmaceutics15020506","volume":"15","author":"M Puccetti","year":"2023","unstructured":"Puccetti, M. et al. Turning microbial AhR agonists into therapeutic agents via drug delivery systems. Pharmaceutics 15, 506 (2023).","journal-title":"Pharmaceutics"},{"key":"11156_CR228","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-021-01107-9","volume":"9","author":"Z Zhao","year":"2021","unstructured":"Zhao, Z. et al. Fecal microbiota transplantation protects rotenone-induced Parkinson\u2019s disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis. Microbiome 9, 226 (2021).","journal-title":"Microbiome"},{"key":"11156_CR229","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.celrep.2019.12.078","volume":"30","author":"ME Goya","year":"2020","unstructured":"Goya, M. E. et al. Probiotic <em>Bacillus subtilis<\/em> Protects against \u03b1-Synuclein Aggregation in <em>C.\u00a0elegans<\/em>. Cell Rep. 30, 367\u2013380.e7 (2020).","journal-title":"Cell Rep."},{"key":"11156_CR230","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1021\/acs.jafc.1c07711","volume":"70","author":"L Wang","year":"2022","unstructured":"Wang, L. et al. Lactobacillus plantarum DP189 reduces \u03b1-SYN aggravation in MPTP-induced Parkinson\u2019s disease mice via regulating oxidative damage, inflammation, and gut microbiota disorder. J. Agric Food Chem. 70, 1163\u20131173 (2022).","journal-title":"J. Agric Food Chem."},{"key":"11156_CR231","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbi.2020.08.001","volume":"90","author":"N Saini","year":"2020","unstructured":"Saini, N. et al. Protective effect of Indole-3-carbinol, an NF-\u03baB inhibitor in experimental paradigm of Parkinson\u2019s disease: In silico and in vivo studies. Brain Behav. Immun. 90, 108\u2013137 (2020).","journal-title":"Brain Behav. Immun."},{"key":"11156_CR232","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1007\/s12035-015-9471-0","volume":"53","author":"J Rzemieniec","year":"2016","unstructured":"Rzemieniec, J. et al. Selective aryl hydrocarbon receptor modulator 3,3\u2019-diindolylmethane impairs AhR and ARNT signaling and protects mouse neuronal cells against hypoxia. Mol. Neurobiol. 53, 5591\u20135606 (2016).","journal-title":"Mol. Neurobiol."},{"key":"11156_CR233","doi-asserted-by":"crossref","unstructured":"Wang, Z. et al. Dietary restriction against Parkinson\u2019s disease: What we know so far. Nutrients. 14, 4108 (2022).","DOI":"10.3390\/nu14194108"},{"key":"11156_CR234","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/(SICI)1097-4547(19990715)57:2<195::AID-JNR5>3.0.CO;2-P","volume":"57","author":"W Duan","year":"1999","unstructured":"Duan, W. & Mattson, M. P. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson\u2019s disease. J. Neurosci. Res. 57, 195\u2013206 (1999).","journal-title":"J. Neurosci. Res"},{"key":"11156_CR235","doi-asserted-by":"publisher","first-page":"18171","DOI":"10.1073\/pnas.0405831102","volume":"101","author":"N Maswood","year":"2004","unstructured":"Maswood, N. et al. Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson\u2019s disease. Proc. Natl. Acad. Sci. USA 101, 18171\u201318176 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"11156_CR236","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/ijms23010288","volume":"23","author":"AS Cannon","year":"2021","unstructured":"Cannon, A. S., Nagarkatti, P. S. & Nagarkatti, M. Targeting AhR as a novel therapeutic modality against inflammatory diseases. Int. J. Mol. Sci. 23, 288 (2021).","journal-title":"Int. J. Mol. Sci."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-11156-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-11156-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-11156-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:02:07Z","timestamp":1792695727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-11156-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":236,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["11156"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-11156-1","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"1387"}}